Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $10.6250 (-1.94%) ($10.6250 - $10.6250) on Mon. Sep. 19, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.97% (three month average) | RSI | 52 | Latest Price | $10.6250(-1.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -1.7% a day on average for past five trading days. | Weekly Trend | IOVA advances 1.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(39%) IWC(37%) IWO(34%) IBUY(33%) IWM(33%) | Factors Impacting IOVA price | IOVA will decline at least -1.985% in a week (0% probabilities). UUP(-15%) VIXM(-10%) UNG(-10%) VXX(-9%) TBT(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.985% (StdDev 3.97%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.08 | 5 Day Moving Average | $11.07(-4.02%) | 10 Day Moving Average | $11.03(-3.67%) | 20 Day Moving Average | $11.08(-4.11%) | To recent high | -18.7% | To recent low | 15.6% | Market Cap | $1.556b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |